SGTX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (10 Aug 2023 @ 16:00):

Stats
Today's Volume	81 878.00
Average Volume	120 683
Market Cap	56.22M
EPS	$0 ( 2024-03-12 )
Next earnings date	( $0 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.515
ATR14	$1.161 (5.17%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-11	Flagship Ventures Fund V General Partner Llc	Sell	113 960	Common Stock
2023-08-11	Eli Lilly & Co	Buy	1 718 493	Common Stock
2023-08-11	Cole Douglas G.	Sell	683	Stock Option (Right to Buy)
2023-08-11	Cole Douglas G.	Sell	683	Stock Option (Right to Buy)
2023-08-11	Oesterle Stephen N.	Sell	683	Stock Option (Right to Buy)

INSIDER POWER
68.75
Last 96 transactions
Buy: 15 034 169 \| Sell: 5 311 777

Volume Correlation

Long: 0.16 (neutral)

Short: 0.00 (neutral)

Signal:(71.261) Neutral

Sigilon Therapeutics, Correlation

10 Most Positive Correlations
OCUL	0.908
ICAD	0.899
MORF	0.885
SVC	0.88
RBBN	0.879
MHUA	0.877
SJ	0.876
MSSA	0.874
VRCA	0.872
USAP	0.868

10 Most Negative Correlations
RGF	-0.902
GSMG	-0.889
ACRX	-0.877
JRJC	-0.868
ESSA	-0.865
IBRX	-0.864
ALLK	-0.86
APEI	-0.859
FLIC	-0.858
BNIXU	-0.857

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sigilon Therapeutics, Correlation - Currency/Commodity

-0.53
( weak negative )

-0.52
( weak negative )

0.17
( neutral )

0.28
( neutral )

0.58
( weak )

0.75
( moderate )

Sigilon Therapeutics, Financials

Annual	2022
Revenue:	$12.94M
Gross Profit:	$12.94M (100.00 %)
EPS:	$-1.340

Q2	2023
Revenue:	$5.90M
Gross Profit:	$5.90M (100.00 %)
EPS:	$-3.00

Q1	2023
Revenue:	$4.86M
Gross Profit:	$4.86M (100.00 %)
EPS:	$-0.230

Q4	2022
Revenue:	$2.64M
Gross Profit:	$2.64M (100.00 %)
EPS:	$-0.170

Financial Reports:

No articles found.

Sigilon Therapeutics,

Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.